- The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells
Pauline Estupina et al, 2017, Oncotarget CrossRef - Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR
Sarah E. Gill et al, 2017, Oncotarget CrossRef - The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages
Houcine Bougherara et al, 2017, Oncotarget CrossRef - Anti-mullerian hormone receptor type II as a Potential Target for Antineoplastic Therapy
A. Ya. Rak et al, 2019, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry CrossRef - Anti-Müllerian hormone: biology and role in endocrinology and cancers
Marek Gowkielewicz et al, 2024, Frontiers in Endocrinology CrossRef - Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II
Cagri Sakalar et al, 2015, Journal of Immunology Research CrossRef - Interaction Study of Different Forms of Human Recombinant Anti-Mullerian Hormone with a Chimeric Analogue of the AMH Type II Receptor
A. Ya. Rak et al, 2021, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry CrossRef - Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
Suparna Mazumder et al, 2020, Oncotarget CrossRef - The role of anti-Mullerian hormone in the context of modern pathogenetic approaches to the treatment of endometriosis (literature review)
N. A. Buralkina et al, 2023, Meditsinskiy sovet = Medical Council CrossRef